Startup profile · funding coverage
Mana Bio
AI-native biotech designing lipid nanoparticles for targeted RNA and gene-therapy delivery.
Stage
See coverage
Status
private
Coverage
full
Why Mana Bio is interesting
Mana.bio uses ML to optimize LNPs beyond the liver — a16z Bio + Health co-led its $19.5M seed as extrahepatic delivery became the bottleneck for genetic medicine.
Key facts
- Seed (Oct 2023): $19.5M co-led by a16z Bio + Health with Base4, NFX, LionBird (PR Newswire)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
Investors in our directory
Funds linked from Mana Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Mana Bio's financing or category context.
Last updated: 2026-07-24